JAMES LUKAS: Open Payments
NPI 1083120687 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,501 in 67 payments from 11 companies in 2025. Trend: 2023 $1,295 · 2024 $1,721 · 2025 $1,501
Food & beverage: $1,392Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $477 |
| Teva Pharmaceuticals USA, Inc. | 13 | $420 |
| Axsome Therapeutics, Inc. | 7 | $161 |
| Neurocrine BioSciences, Inc. | 7 | $155 |
| E.R. Squibb & Sons, L.L.C. | 5 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Lundbeck LLC | 1 | $28 |
| Alkermes, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: VRAYLAR, AUSTEDO XR, Auvelity, INGREZZA, COBENFY, UZEDY, CAPLYTA, REXULTI.
Industry payments across MD — which companies pay providers there.
